- GSK shelves cough drug acquired in $2B dealMixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.BioPharma Dive · 11d ago↗ source
- STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.STAT · 11d ago↗ source
- STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and moreThe number of active medication shortages in the U.S. rose to 227 in the second quarter of 2026STAT · 11d ago↗ source